LMO2 and acute myeloid leukemia: Down-regulation of miR-223 also has been demonstrated in hepatocellular carcinoma [30], acute myeloid leukemia [31] and chronic lymphocytic leukemia [32,33], and shown to regulate the important hematopoietic regulator LMO2 [34] that is commonly expressed in lymphoma [35].